| S. No. |
Conjugate |
Indication |
Marketing year |
Company |
| 1 |
PEG–adenosine deaminase (Adagen) |
SCID syndrome |
1990 |
Enzon |
| 2 |
PEG–asparaginase (Oncaspar) |
Acute lymphoblastic leukaemia |
1994 |
Enzon |
| 3 |
SMANCS (Zinostatin, Stimalamer) |
Hepatocellular carcinoma |
1993 |
Yamanouchi Pharmaceutical |
| 4 |
Linear PEG–interferon α2b (PEG–Intron) |
Hepatitis C, clinical evaluation on cancer, multiple sclerosis and HIV/AIDS |
2000 |
Schering Plough/Enzon |
| 5 |
Branched PEG–interferon a2a (Pegasys) |
Hepatitis C |
2002 |
Roche/Nektar |
| 6 |
PEG–growth hormone receptor antagonist |
Acromegaly |
2002 |
Pfizer (Pharmacia) |
| 7 |
PEG–G-CSF (Pegfilgrastim, Neulasta) |
Prevention of neutropenia associated with cancer chemotherapy |
2002 |
Amgen |
| 8 |
Branched PEG–anti-VEGF aptamer |
Age-related macular degeneration |
2004 |
EyeTech Pharmaceuticals (now OSI Pharmaceutical)/Pfizer |
| 9 |
PEG–anti-TNF Fab |
Rheumatoid arthritis and Crohn’s disease |
2008 |
UCB (formerly Celltech) |
